Iantrek reports 37% IOP reduction in bio-reinforced canaloplasty study

Six-month first-in-human data showed a 37% drop in intraocular pressure and no serious adverse events across 52 treated eyes.

The Biotech Times Editorial Team By The Biotech Times Editorial Team AI level 2 of 5
AI level 2 of 5: drafted by our AI editorial assistant from the company's announcement; fact-checked, edited and signed off by Mark Walker, Editorial Director. What the levels mean
A pair of human lungs is suspended within a transparent, internally lit medical device with red tubing, situated in a bright, sterile laboratory with large windows.

Iantrek has released topline six-month results from a first-in-human investigator-initiated study of bio-reinforced canaloplasty, a procedure combining canal dilation with homologous allograft tissue to target the trabecular outflow pathway in glaucoma patients. The results, timed to coincide with the American Academy of Ophthalmology annual meeting in New Orleans, add clinical weight to the company's "bio-interventional ophthalmic surgery" (BIOS) platform.

Across 52 treated eyes, mean intraocular pressure fell by 37.2% from a baseline of 22.4 mmHg at six months, with 90% of eyes reaching 18 mmHg or below. Mean glaucoma medication use dropped by 49.1% from a baseline of 1.2 medications. No serious ocular adverse events were recorded, and no eye required secondary surgical intervention for IOP control through the six-month window.

Clinical context

The study was observational, single-centre, and investigator-initiated, which the company acknowledges. Full data remain subject to further analysis ahead of formal publication, and the results should be read accordingly. That said, the magnitude of IOP reduction and medication burden figures are clinically meaningful if they hold at longer follow-up, and the absence of serious adverse events at six months is encouraging for an early-stage programme.

At the same AAO meeting, Iantrek will present two analyses from its CREST study, which evaluates bio-reinforced cyclodialysis targeting the complementary uveoscleral outflow pathway. One presentation, led by Reena Garg, MD, covers surgical outcomes and safety across more than 500 cases; a second on-demand session examines one-year IOP outcomes comparing one versus two allograft spacers. Together, the datasets are designed to position BIOS as a framework capable of addressing both major aqueous outflow pathways in sequence or combination.

Chief executive Adam Szaronos said the company had already performed more than 10,000 bio-reinforced cyclodialysis procedures in the US and was now bringing "that same restorative, natural approach" to the trabecular pathway with canaloplasty.

Market landscape and regulatory path

Glaucoma surgery sits in a competitive segment of the medical-device market. The minimally invasive glaucoma surgery category has grown rapidly since the mid-2010s, with devices from iStent (Glaukos), Hydrus (Alcon) and XEN (AbbVie) establishing reimbursement pathways and building clinical datasets. Iantrek's differentiation rests on the use of allograft biological tissue rather than synthetic implants, which the company argues better preserves natural anatomy.

The commercial case is supported by a meaningful addressable population. Iantrek cites an estimated 3.5 million eyes in the US that have previously undergone MIGS, many of which may require additional intervention as the disease progresses, alongside roughly 400,000 canal-based procedures performed annually.

The company's lead trabecular product, AlloSpan Canal, is currently in the BOOST clinical study at select US sites and is reported under established Category I CPT code 66175, for which the AAO issued reimbursement guidance earlier in 2026. A commercial launch is targeted for 2027. Securing that reimbursement framework ahead of launch reduces one of the typical adoption barriers for novel surgical devices and gives Iantrek a cleaner path to uptake among glaucoma surgeons already familiar with canal-based procedures.

Sector

Topic

Geography